FDA Lifts Partial Clinical Hold on Prosetin, MAP4K Inhibitor, Phase 1 Trial in ALS Patients.

Published Date: 11 Apr 2024

PRO-101 is a phase 1 study that evaluates prosetin's safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy volunteers and ALS patients.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

2.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

3.

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

4.

Charles III, King of Kings, is Cancerous.

5.

The Truth About Apple AirPods


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot